WP
BEAM icon

Woodline Partners’s Beam Therapeutics BEAM Stock Holding History

Woodline Partners’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-993,066
Closed -$27.5M – 1039
2025
Q4 		$27.5M Buy
993,066
+446,507
+82% +$11.4M 0.11% 251
2025
Q3 		$13.3M Sell
546,559
-214,939
-28% -$4.28M 0.06% 372
2025
Q2 		$13M Buy
761,498
+887
+0.1% +$15.4K 0.07% 373
2025
Q1 		$14.9M Buy
760,611
+478,491
+170% +$12.5M 0.1% 282
2024
Q4 		$7M Buy
+282,120
New +$7.2M 0.05% 420
2023
Q4 		– Sell
-449,732
Closed -$10.8M – 494
2023
Q3 		$10.8M Buy
+449,732
New +$12.1M 0.13% 213
2022
Q4 		– Sell
-83,134
Closed -$3.96M – 761
2022
Q3 		$3.96M Buy
+83,134
New +$4.74M 0.06% 340

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Woodline Partners's BEAM Position: Q1 2026 in Review

Woodline Partners sold out of Beam Therapeutics (BEAM) in Q1 2026, closing a stake of 993,066 shares — an estimated $27.5M sold.

Woodline Partners first reported a position in BEAM in Q3 2022 and held it in 7 quarters. The position peaked at $27.5M in Q4 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Woodline Partners reported no remaining Beam Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Woodline Partners sold 993,066 Beam Therapeutics shares in Q1 2026, an estimated $27.5M.
  • Woodline Partners first reported a position in Beam Therapeutics in Q3 2022 and held it in 7 quarters.
  • Woodline Partners's Beam Therapeutics position peaked at $27.5M in Q4 2025.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.